Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, Karnieli E, Assalia A, Prager R, Prager G
Medical University of Vienna, Waehringer Guertel, 18-20, 1090, Vienna, Austria.
Surg Endosc. 2009 Sep;23(9):1955-60. doi: 10.1007/s00464-008-0222-4. Epub 2008 Dec 6.
The TANTALUS system (MetaCure Ltd.) is a minimally invasive implantable gastric stimulation modality that does not exhibit malabsorptive or restrictive characteristics. The device applies gastric contractility modulation (GCM) signals to the stomach antrum. The signals are delivered in synchronization to the native electrical activity of the stomach during meals. Retrospective analysis of previous studies indicated that type 2 diabetes mellitus (T2DM) subjects on oral medication with hemoglobin A1c (HbA1c) between 7.5% and 9.5% are the population with most potential benefit from the treatment. The current study includes subjects enrolled prospectively within that range of HbA1c.
To prospectively investigate the potential effect of the TANTALUS system on glycemic control and weight in overweight subjects with T2DM.
In this European multicenter, open-label study, 13 T2DM obese (6 male, 7 female, BMI 37.2 +/- 1.0 kg/m(2), range 30.4-44.0 kg/m(2)) subjects treated with oral antidiabetic medications but with poor glycemic control (HbA1c > or = 7%, range 7.3-9.5%) were implanted laparoscopically with the TANTALUS system.
Thirteen subjects that had completed 3 months of treatment showed a significant reduction in HbA1c from 8.0 +/- 0.2% to 6.9 +/- 0.1% (p < 0.05), whereas fasting blood glucose decreased from 175 +/- 6 mg/dL to 127 +/- 8 mg/dL (p < 0.05). The glycemic improvement was accompanied by reduction in weight from 104.4 +/- 4.4 kg to 99.7 +/- 4.8 kg, and in waist circumference from 122.3 +/- 3.2 cm to 117.0 +/- 3.0 cm.
Interim results with the TANTALUS system suggest that this stimulation regime can potentially improve glucose levels and induce moderate weight loss in obese T2DM subjects on oral antidiabetic therapy with poor glycemic control. Further evaluation is required to determine whether this effect is due to induced weight loss and/or due to direct signal-dependent mechanisms.
TANTALUS系统(MetaCure有限公司)是一种微创可植入式胃刺激装置,不具有吸收不良或限制吸收的特性。该装置将胃收缩力调节(GCM)信号施加于胃窦。这些信号在进餐期间与胃的固有电活动同步传递。对既往研究的回顾性分析表明,糖化血红蛋白(HbA1c)在7.5%至9.5%之间的口服药物治疗的2型糖尿病(T2DM)患者是最有可能从该治疗中获益的人群。本研究纳入了HbA1c在此范围内的前瞻性入组患者。
前瞻性研究TANTALUS系统对超重T2DM患者血糖控制和体重的潜在影响。
在这项欧洲多中心、开放标签研究中,13例接受口服抗糖尿病药物治疗但血糖控制不佳(HbA1c≥7%,范围7.3 - 9.5%)的T2DM肥胖患者(6例男性,7例女性,BMI 37.2±1.0kg/m²,范围30.4 - 44.0kg/m²)通过腹腔镜植入TANTALUS系统。
13例完成3个月治疗的患者HbA1c从8.0±0.2%显著降至6.9±0.1%(p<0.05),空腹血糖从175±6mg/dL降至127±8mg/dL(p<0.05)。血糖改善的同时体重从104.4±4.4kg降至99.7±4.8kg waist circumference从122.3±3.2cm降至117.0±3.0cm。
TANTALUS系统的中期结果表明,这种刺激方案可能改善血糖水平,并使接受口服抗糖尿病治疗且血糖控制不佳的肥胖T2DM患者适度减重。需要进一步评估以确定这种效果是由于体重减轻还是由于直接的信号依赖机制。